The Nasdaq Biotechnology Index rose over 2.6%, outperforming the broader US stock market. Among constituents, Sarepta Therapeutics surged 34.98%, Summit Therapeutics Plc. rose 15.53%, Enliven Therapeutics increased 14.06%, Upstream Bio gained 12.07%, Taysha Gene climbed 10.90%, Gossamer Bio advanced 10.61%, and Oruka Therapeutics was up 9.80%. Conversely, Aardvark Therapeutics fell 6.10%, ADMA Biologics dropped 15.23%, Anavex Life Sciences declined 34.61%, and Maze Therapeutics fell 35.24%Wallstreetcn·Mar 25, 2026 at 08:50 PMXBI-1.38%TSHA-1.12%
The Nasdaq Biotechnology Index fell by more than 1.2%. Among them, Medpace dropped 15.90%, Tectonic Therapeutic fell 15.22%, Regenxbio decreased 14.31%, Humacyte declined 13.93%, and Anavex Life Sciences fell 8.74%. In contrast, Mesoblast rose 7.21%, Personalis increased 10.03%, Invivyd gained 10.14%, PepGen surged 17.99%, and Neumora Therapeutics jumped 25.10%Wallstreetcn·Feb 10, 2026 at 11:10 PMIDNA-0.32%RGNX-6.83%
The Nasdaq Biotechnology Index closed up over 1.9%. Anavex Life Sciences rose 24.93%, Fortrea Holdings rose 16.16%, Erasca rose 14.53%. Regeneron Pharmaceuticals fell 2.69%, Aurinia Pharmaceuticals fell 6.85%, NewAmsterdam Pharma fell 8.71%, Adaptive Biotechnologies fell 8.83%Wallstreetcn·Dec 3, 2025 at 09:29 PMAVXL-2.21%ERAS+2.49%
The Nasdaq Biotechnology Index closed up nearly 1.4%, closely mirroring the performance of the Dow Jones Industrial Average. Among the constituent stocks, Esperion rose 16.09%, ARS Pharmaceuticals rose 15.50%, Anavex Life Sciences rose 12.34%, Personalis rose 12.31%, Autolus Therapeutics rose 12.10%, and Aura Biosciences rose 11.09%. AC Immune fell 5.84%, LENZ Therapeutics fell 6.51%, and Cullinan Oncology LLC fell 8.82%Wallstreetcn·Nov 25, 2025 at 09:27 PMPSNL+0.19%SPRY-6.71%
